Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

Inclusion Criteria: * Written informed consent obtained from parent or legal guardian * Birth weight 500 to 1250 g, inclusive * Age 3 - 5 days (49 to 120 hours), inclusive * Expected to require IV access for medical care through day of life 14 Exclusion Criteria: * Already received or likely to receive prior to first infusion of Study Drug: * IGIV or \*immune globulin for prevention of Hepatitis B * Receiving an agent for prevention of staphylococcal catheter related or nosocomial infections (e.g., vancomycin) * Active sepsis, as defined by one of the following: * culture proven early onset sepsis and not clinically stable; or * clinical signs of sepsis and pending blood cultures; if the blood cultures are negative after 48 hours and the infant is clinically stable, the infant may be randomized * Severe congenital anomaly, where the prospects for survival, the medical complications and treatment, would compromise the study related outcome evaluation(s) in the Investigator's opinion * Diagnosis of congenital immunodeficiency * Evidence of significant fluid overload or significant volume depletion * Evidence of abnormal renal function as measured by serum creatinine \> 1.6 mg/dL